While in the dual-armed MyxV + αPD-L1 treatment group, the ratio of tumor-infiltrated CD4+ T-cells was similar to that of the αPD-L1 single treatment group, the percentage of activated T-cells, IFN-γ+ CD4+ T-cells, but not IFN-γ+ CD8+ T-cells, was significantly increased in tumor infiltrated CD3+ T-cell population in the combination treatment of αPD-L1 and MyxV_CD47/IFN-γ (Figure 6B). The gene discussed is IFNG; the disease is neoplasm.